BioGaia AB (publ) - Asset Resilience Ratio
BioGaia AB (publ) (BIOG-B) has an Asset Resilience Ratio of 50.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how BioGaia AB (publ)'s Asset Resilience Ratio has changed over time. Check BioGaia AB (publ) strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down BioGaia AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BioGaia AB (publ) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr801.31 Million | 50.15% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr801.31 Million | 50.15% |
Asset Resilience Insights
- Very High Liquidity: BioGaia AB (publ) maintains exceptional liquid asset reserves at 50.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BioGaia AB (publ) Industry Peers by Asset Resilience Ratio
Compare BioGaia AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for BioGaia AB (publ) (2006–2025)
The table below shows the annual Asset Resilience Ratio data for BioGaia AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 50.15% | Skr801.31 Million ≈ $86.23 Million |
Skr1.60 Billion ≈ $171.95 Million |
-10.03pp |
| 2024-12-31 | 60.18% | Skr1.22 Billion ≈ $131.72 Million |
Skr2.03 Billion ≈ $218.89 Million |
-6.01pp |
| 2023-12-31 | 66.18% | Skr1.54 Billion ≈ $166.18 Million |
Skr2.33 Billion ≈ $251.09 Million |
-1.04pp |
| 2022-12-31 | 67.23% | Skr1.49 Billion ≈ $160.17 Million |
Skr2.21 Billion ≈ $238.26 Million |
-2.54pp |
| 2021-12-31 | 69.77% | Skr1.48 Billion ≈ $159.78 Million |
Skr2.13 Billion ≈ $229.01 Million |
-6.95pp |
| 2020-12-31 | 76.72% | Skr1.47 Billion ≈ $157.97 Million |
Skr1.91 Billion ≈ $205.90 Million |
+43.86pp |
| 2019-12-31 | 32.86% | Skr218.81 Million ≈ $23.55 Million |
Skr665.90 Million ≈ $71.66 Million |
-11.05pp |
| 2018-12-31 | 43.91% | Skr289.79 Million ≈ $31.19 Million |
Skr659.97 Million ≈ $71.02 Million |
-10.05pp |
| 2017-12-31 | 53.96% | Skr310.86 Million ≈ $33.45 Million |
Skr576.11 Million ≈ $62.00 Million |
+4.25pp |
| 2016-12-31 | 49.71% | Skr243.08 Million ≈ $26.16 Million |
Skr488.98 Million ≈ $52.62 Million |
+49.71pp |
| 2015-12-31 | 0.00% | Skr13.00K ≈ $1.40K |
Skr473.18 Million ≈ $50.92 Million |
0.00pp |
| 2014-12-31 | 0.00% | Skr13.00K ≈ $1.40K |
Skr415.61 Million ≈ $44.73 Million |
-0.02pp |
| 2013-12-31 | 0.02% | Skr80.00K ≈ $8.61K |
Skr383.42 Million ≈ $41.26 Million |
+0.01pp |
| 2012-12-31 | 0.02% | Skr80.00K ≈ $8.61K |
Skr517.02 Million ≈ $55.64 Million |
-0.01pp |
| 2011-12-31 | 0.03% | Skr80.00K ≈ $8.61K |
Skr279.83 Million ≈ $30.11 Million |
-0.01pp |
| 2010-12-31 | 0.04% | Skr80.00K ≈ $8.61K |
Skr227.82 Million ≈ $24.52 Million |
-0.01pp |
| 2009-12-31 | 0.04% | Skr80.00K ≈ $8.61K |
Skr179.81 Million ≈ $19.35 Million |
-0.52pp |
| 2007-12-31 | 0.56% | Skr620.00K ≈ $66.72K |
Skr110.77 Million ≈ $11.92 Million |
-0.35pp |
| 2006-12-31 | 0.91% | Skr830.00K ≈ $89.32K |
Skr90.76 Million ≈ $9.77 Million |
-- |
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more